Skip to content
Screener

Regenxbio RGNX Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue$21.4MMiss by $88.7M
EPS-$1.38Miss by $0.25
Revenue estimate$110.0M
EPS estimate-$1.13

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$15.9M
EPS estimate-$1.21

Financials

Q2 2025

Income statement

See full
Revenue$21.4M-4.2%
Operating income-$63.3M-12.9%
Net income-$70.9M-33.7%
EPS (diluted)-$1.38-31.4%

Balance sheet

See full
Cash & equivalents$79.6M+37.7%
Total debt$77.7M-9.2%
Total equity$213.7M-38.6%
Total assets$581.0M+2.0%

Cash flow

See full
Operating cash flow-$49.3M-8.5%
CapEx$391.0K-17.5%
Free cash flow-$49.7M-8.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$431.33M-19.4%
Enterprise value$429.47M-23.7%
P/S2.8×-3.2×

Profitability

See full
Operating margin-105.7%-40.5pp
Net margin-112.7%-41.5pp
FCF margin-58.2%-24.6pp

Returns & leverage

See full
Return on equity-62.5%-1.4pp
Debt / equity0.4×+0.1×
Current ratio3.1×-0.4×

Segments

By product

See full
Zolgensma And Itvisma Royalties$18.4M—
Nippon Shinyaku Services$2.7M—
Other Service Revenue$174.0K-61.2%

FAQ

When did Regenxbio report Q2 2025 earnings?
Regenxbio (RGNX) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Regenxbio's Q2 2025 revenue and EPS?
Regenxbio reported revenue of $21.4M and eps of $-1.38 for Q2 2025.
Did Regenxbio beat estimates in Q2 2025?
Revenue missed the consensus estimate of $110.0M by $88.7M. EPS missed the consensus estimate of $-1.13 by $0.25.
How did Regenxbio's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 4.2% from $22.3M a year earlier and eps declined 31.4% from $-1.05.
Where can I find Regenxbio's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-174947) and the 10-Q periodic report (0001193125-25-174953) directly on SEC EDGAR. The filing index links above go to sec.gov.